Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Clin Liver Dis
; 27(4): 809-818, 2023 11.
Article
in En
| MEDLINE
| ID: mdl-37778771
ABSTRACT
In treatment-naïve patients with chronic hepatitis B virus (HBV) infection, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide have a minimal or no risk of drug-resistance. These 3 nucleos(t)ide analog agents are highly potent inducing high rate of virologic response (reducing serum HBV DNA to levels undetectable by polymerase chain reaction assays) in most treatment-naïve patients. Our randomized trials have demonstrated that monotherapy with TDF can provide a successful virological response in most of the heavily pretreated patients with multidrug resistance to ETV or adefovir.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hepatitis B, Chronic
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Clin Liver Dis
Journal subject:
GASTROENTEROLOGIA
Year:
2023
Document type:
Article